Richard C Franzese
Overview
Explore the profile of Richard C Franzese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
1
Citations
9
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Struemper H, Rathi C, Muliaditan M, Goulooze S, Franzese R, Mantero A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2025 Feb;
PMID: 39985158
Tumor size-overall survival (TS-OS) models can support decision-making in oncology drug development by predicting long-term OS based on TS data from early data cuts and baseline patient factors. The current...
2.
Goulooze S, Muliaditan M, Franzese R, Mantero A, Visser S, Melhem M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2025 Feb;
PMID: 39985154
The gold standard for regulatory approval in oncology is overall survival (OS). Because OS data are initially limited, early drug development decisions are often based on early efficacy endpoints, such...
3.
Franzese R, McFadyen L, Watson K, Riccobene T, Carrothers T, Vourvahis M, et al.
Clin Pharmacol Ther
. 2021 Oct;
111(3):635-645.
PMID: 34687548
Increasing prevalence of infections caused by antimicrobial-resistant gram-negative bacteria represents a global health crisis, and while several novel therapies that target various aspects of antimicrobial resistance have been introduced in...